stoxline Quote Chart Rank Option Currency Glossary
  
VYNE Therapeutics Inc. (VYNE)
2.55  0.02 (0.79%)    05-30 16:00
Open: 2.56
High: 2.59
Volume: 47,454
  
Pre. Close: 2.53
Low: 2.5
Market Cap: 37(M)
Technical analysis
2024-05-30 4:45:19 PM
Short term     
Mid term     
Targets 6-month :  3.29 1-year :  3.6
Resists First :  2.82 Second :  3.08
Pivot price 2.68
Supports First :  2.4 Second :  1.99
MAs MA(5) :  2.57 MA(20) :  2.68
MA(100) :  2.36 MA(250) :  3.27
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  17.6 D(3) :  15.8
RSI RSI(14): 45.4
52-week High :  6.78 Low :  1.66
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VYNE ] has closed above bottom band by 16.3%. Bollinger Bands are 41.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.59 - 2.61 2.61 - 2.62
Low: 2.47 - 2.49 2.49 - 2.5
Close: 2.52 - 2.55 2.55 - 2.58
Company Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Headline News

Thu, 09 May 2024
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research

Wed, 08 May 2024
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - Defense World

Tue, 07 May 2024
VYNE Therapeutics receives FDA approval for trial of VYN202 - Clinical Trials Arena

Mon, 06 May 2024
VYNE Therapeutics gets FDA nod for new drug trial - Investing.com

Sat, 27 Apr 2024
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation - Simply Wall St

Sat, 13 Apr 2024
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 14 (M)
Held by Insiders 9.59e+006 (%)
Held by Institutions 8.4 (%)
Shares Short 86 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 530.6 %
Return on Equity (ttm) -30.3 %
Qtrly Rev. Growth 423000 %
Gross Profit (p.s.) -24.02
Sales Per Share -86.61
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 81960
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android